Morgan Stanley raised the firm’s price target on Qiagen (QGEN) to EUR 42 from EUR 41 and keeps an Equal Weight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen price target raised to $55 from $53 at Barclays
- Goldman Sachs’ Significant Stake in QIAGEN Revealed by AFM Notification
- Qiagen N.V. Receives Notification of Significant Shareholding by Massachusetts Financial Services
- Goldman Sachs’ Voting Rights in QIAGEN Revealed by AFM
- Qiagen downgraded to Neutral from Buy at Citi